Publication
pH-responsive hybrid nanoassemblies for cancer treatment: formulation development, optimization, and In vitro therapeutic performance
| dc.contributor.author | Teixeira, Patrícia V. | |
| dc.contributor.author | Adega, Filomena | |
| dc.contributor.author | Martins-Lopes, Paula | |
| dc.contributor.author | Machado, Raul | |
| dc.contributor.author | Lopes, Carla Martins | |
| dc.contributor.author | Lúcio, Marlene | |
| dc.date.accessioned | 2024-01-30T14:34:47Z | |
| dc.date.available | 2024-01-30T14:34:47Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Current needs for increased drug delivery carrier efficacy and specificity in cancer necessitate the adoption of intelligent materials that respond to environmental stimuli. Therefore, we developed and optimized pH-triggered drug delivery nanoassemblies that exhibit an increased release of doxorubicin (DOX) in acidic conditions typical of cancer tissues and endosomal vesicles (pH 5.5) while exhibiting significantly lower release under normal physiological conditions (pH 7.5), indicating the potential to reduce cytotoxicity in healthy cells. The hybrid (polymeric/lipid) composition of the lyotropic non-lamellar liquid crystalline (LNLCs) nanoassemblies demonstrated high encapsulation efficiency of the drug (>90%) and high drug loading content (>7%) with colloidal stability lasting at least 4 weeks. Confocal microscopy revealed cancer cellular uptake and DOX-loaded LNLCs accumulation near the nucleus of human hepatocellular carcinoma cells, with a large number of cells appearing to be in apoptosis. DOX-loaded LNLCs have also shown higher citotoxicity in cancer cell lines (MDA-MB 231 and HepG2 cell lines after 24 h and in NCI-H1299 cell line after 48 h) when compared to free drug. After 24 h, free DOX was found to have higher cytotoxicity than DOX-loaded LNLCs and empty LNLCs in the normal cell line. Overall, the results demonstrate that DOX-loaded LNLCs have the potential to be explored in cancer therapy. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Teixeira, P.V.; Adega, F.; Martins-Lopes, P.; Machado, R.; Lopes, C.M.; Lúcio, M. pH-responsive hybrid nanoassemblies for cancer treatment: formulation development, optimization, and In vitro therapeutic performance. Pharmaceutics 2023, 15, 326. https://doi.org/10.3390/ | pt_PT |
| dc.identifier.doi | 10.3390/pharmaceutics15020326 | pt_PT |
| dc.identifier.eissn | 1999-4923 | |
| dc.identifier.uri | http://hdl.handle.net/10284/12625 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | MDPI | pt_PT |
| dc.subject | Cancer | pt_PT |
| dc.subject | Chemotherapeutic agents | pt_PT |
| dc.subject | Doxorubicin | pt_PT |
| dc.subject | Drug-delivery systems | pt_PT |
| dc.subject | Lyotropic nonlamellar liquid crystalline nanoassemblies | pt_PT |
| dc.title | pH-responsive hybrid nanoassemblies for cancer treatment: formulation development, optimization, and In vitro therapeutic performance | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 2 | pt_PT |
| oaire.citation.startPage | 326 | pt_PT |
| oaire.citation.title | Pharmaceutics | pt_PT |
| oaire.citation.volume | 15 | pt_PT |
| person.familyName | Lopes | |
| person.givenName | Carla | |
| person.identifier.ciencia-id | 901D-160C-633E | |
| person.identifier.orcid | 0000-0001-5080-032X | |
| person.identifier.rid | M-4689-2016 | |
| person.identifier.scopus-author-id | 26649517700 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | d2a48cfe-9258-4916-99be-bbcb710f6605 | |
| relation.isAuthorOfPublication.latestForDiscovery | d2a48cfe-9258-4916-99be-bbcb710f6605 |